Silence Therapeutics plc
NASDAQ:SLNBiotechnology
+$0.19 today
- Market cap
- $935.23M
- Beta
- 1.48
- P/E (TTM)
- -3.9
- EPS (TTM)
- -$1.80
Volume 1.21M
Average 0.31M
SLN EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Silence Therapeutics plcNASDAQ: SLN
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$14.83M, compared with -$36.73M a year earlier. Trailing-twelve-month EBITDA was -$78.13M.
Context
- EBITDA amounted to 15750.6% of revenue in FY2025, up 15637.4 pp from a year earlier.
- EBITDA grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 4 analysts of -$3.84M (+95.6%) for the fiscal year ending Dec 2026, a step up from the -79.7% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$14.83M-27.2% QoQ
- Last fiscal yearDec 2025
- -$88.05M-79.7% YoY
- LTMMar 2026
- -$78.13M— YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +59.6% | +95.5% | +35.8 pp |
| 1 year | -79.7% | +95.6% | +175.4 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
Mixed currencies · from the income statement
- Latest · FY2025
- (88.05M) USD
- Year-over-year change
- —
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (88.05M) | — |
| FY2024 | 2024-12-31 | (48.99M) | +1.6% |
| FY2023 | 2023-12-31 | (49.78M) | -24.6% |
| FY2022 | 2022-12-31 | (39.94M) | +12.1% |
| FY2021 | 2021-12-31 | (45.42M) | — |
EBITDA vs competitors
How SLN compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- EBITDA amounts to 8478.5% of revenue for SLN, versus a peer median of 148.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $124.95M USD | +217.3% | — | 5.7% | |
| LTM Mar 2026 | -€42.88M EUR | -67.7% | — | 319.0% | |
| LTM Mar 2026 | -$53.46M USD | -44.4% | — | — | |
| LTM Mar 2026 | -$67.53M USD | -3.7% | — | 148.9% | |
| FY2025 | -$76.5M USD | — | — | 410.9% | |
| LTM Mar 2026 | -$78.13M USD | — | — | 8478.5% | |
| LTM Mar 2026 | -$174.59M USD | -68.4% | — | 243.2% | |
| LTM Sep 2026 | -$473.54M USD | -208.3% | — | 49.3% | |
| LTM Sep 2026 | -$603.58M USD | -466.2% | — | 133.9% | |
ADRXADARx Pharmaceuticals, Inc. | — | — | — | — | — |
| Peer median (excluding SLN) | — | -67.7% | — | 148.9% | |
Competitors are the stored peer set for SLN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 · GBP | FY2022 Dec 2022 · GBP | FY2023 Dec 2023 · GBP | FY2024 Dec 2024 · GBP | FY2025 Dec 2025 · USD |
|---|---|---|---|---|---|
| Revenue | 12.42M | 17.65M | 25.38M | 43.26M | 559K |
| Cost of Revenue | 7.46M | 10.97M | 10.32M | 11.81M | 215K |
| Gross Profit | 4.96M | 6.68M | 15.06M | 31.45M | 344K |
| Gross Margin | 39.9% | 37.8% | 59.3% | 72.7% | 61.5% |
| Research & Development | 30.77M | 35.5M | 44.03M | 67.88M | 67.75M |
| Selling, General & Admin | 20.01M | 20.94M | 20.64M | 26.88M | 22.34M |
| Operating Expenses | 50.77M | 56.44M | 64.66M | 94.77M | 90.1M |
| Depreciation & Amortization | 427K | 485.86K | 498K | 593K | 555K |
| EBITDA | (45.42M) | (39.94M) | (49.78M) | (48.99M) | (88.05M) |
| EBITDA Margin | -365.9% | -226.2% | -196.2% | -113.2% | -15750.6% |
| Operating Income | (45.81M) | (49.76M) | (49.6M) | (63.32M) | (89.75M) |
| Operating Margin | -369.0% | -281.9% | -195.5% | -146.4% | -16056.0% |
| Interest Income | 10K | 226K | 1.45M | 4.47M | 3.48M |
| Interest Expense | 8K | 47K | 34K | 0 | 0 |
| Other Income / Expenses | (42K) | 9.29M | (706K) | 18.86M | 1.15M |
| Income Before Tax | (45.86M) | (40.47M) | (50.31M) | (44.46M) | (88.6M) |
| Pre-Tax Margin | -369.4% | -229.3% | -198.3% | -102.8% | -15849.9% |
| Income Tax Expense | (6.45M) | 560.85K | (7.04M) | 845K | 11K |
| Net Income | (39.41M) | (41.03M) | (43.27M) | (45.31M) | (88.61M) |
| Net Margin | -317.4% | -232.4% | -170.5% | -104.7% | -15851.9% |
| EPS (Basic) | (1.35) | (3.78) | (3.48) | (2.37) | (1.89) |
| EPS (Diluted) | (1.35) | (3.78) | (3.48) | (2.37) | (1.89) |
| Weighted Avg Shares | 29.65M | 10.73M | 12.36M | 15.42M | 47.23M |
| Weighted Avg Shares (Diluted) | 29.65M | 10.73M | 12.36M | 15.42M | 47.23M |
Silence Therapeutics plc
NASDAQ:SLN
Intrinsic Alpha fair value
Locked
Current Price
$19.80
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.